Stratec Se · XETR:SBS
Stratec — Investor Presentation (October 2026)
27 slides from Stratec's investor presentation, October 2026
Slide 1: IR Presentation October 2026
IR PRESENTATION October 2026
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Forward-looking statements involve risks. This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realis
Slide 3: STRATEC at a Glance
STRATEC AT A GLANCE Leading OEM player for automation solutions for the diagnostics industry and translational research Three decades of experience in highly regulated healthcare markets and growing technology pool Around 1,400 employees worldwide Around 50% allocable to R&D Production sit
Slide 4: Unique Position Within the Value Chain
UNIQUE POSITION WITHIN THE VALUE CHAIN Shared responsibilities STRATEC provides instrumentation, consumables, software and automation solutions Analyzer Market OEM development and manufacturing Partner Systems Access Several thousand automated analyzer systems manufactured annually Wide range
Slide 5: Active in Fast Growing Segments: IVD Market Segments
ACTIVE IN FAST GROWING SEGMENTS IVD MARKET SEGMENTS / IVD MARKET: ~90 BILLION USD IVD market by technologies Focus on market segments with above-average complexity and growth Molecular Diagnostics Random access analyzer systems (mid-to-high throughput) Smart consumables (multiplexing) POC devi
Slide 6: Benefitting from Outsourcing Trend
BENEFITTING FROM OUTSOURCING TREND OUTSOURCED VS IN HOUSE INSTRUMENTATION MARKET Outsourcing to specialized players set to continue, due to: The majority of instrumentation equipment in the IVD market is still developed in-house by diagnostics Engineering of automation solutions often not a core com
Slide 7: Strong Recurring Revenue Base
STRONG RECURRING REVENUE BASE Service parts and consumables 41% of sales Smart consumables Service and spare parts Maintenance parts Spare parts Classic plastic consumables (eg. Pipetting tips, reaction vessels) Peristaltic Pump Smart consumables (highly complex cartridges; microfluidics,
Slide 8: Strong Long-Term Customer Relationships
STRONG LONG-TERM CUSTOMER RELATIONSHIPS A SELECTION OF STRATEC CUSTOMERS Sales 2025 Sales 2025 15 # Global top 20 IVD companies (USD bn) # Global top 20 IVD companies (USD bn) 1 Roche 16.9 11 Illumina 2.3 2 Danaher 9.9 12 Natera 2.3 of the global top 20 IVD companies are STRATEC customers 3 Abbott 8
Slide 9: Global Set Up Aligned with Customers: Locations
GLOBAL SET UP ALIGNED WITH CUSTOMERS LOCATIONS OF THE STRATEC GROUP Site overview Birkenfeld, Germany Budapest, Hungary Anif, Austria Beringen, Switzerland HQ, R&D, Instrumentation Instrumentation Production, R&D, Consumables Production, Instrumentation Production Production, Sales Sales Sales Cluj,
Slide 10: H1 2026 at a Glance: Highlights and Achievements
H1 2026 AT A GLANCE HIGHLIGHTS AND ACHIEVEMENTS Improved performance 2026 guidance Stable profitability Pipeline progress in Q2 confirmed • Improved performance in • Profitability in H1 2026 nearly • Ongoing high demand from • Based on current orders and Q2 helped narrow the year-on- at the same lev
Slide 11: Financials at a Glance
FINANCIAL REVIEW FINANCIALS AT A GLANCE1 € 000s H1/2026 H1/2025 Change Q2/2026 Q2/2025 Change -5.1% +1.5% Sales 112,536 118,590 59,110 58,227 (cc: -3.3%) (cc: +2.4%) Adjusted EBITDA 15,691 16,070 -2.4% 10,999 6,765 +62.6% Adjusted EBITDA margin (%) 13.9 13.6 +30 bps 18.6 11.6 +700 bps Adjusted EBIT
Slide 12: Adjustments H1 2026
FINANCIAL REVIEW ADJUSTMENTS H1 2026 EBIT Consolidated net income € 000s H1 2026 H1 2025 € 000s H1 2026 H1 2025 Adjusted EBIT 7,731 8,487 Adjusted consolidated net income 4,112 4,978 Adjustments: Adjusted earnings per share in € (basic) 0.34 0.41 PPA amortization -1,052 -1,617 Adjustments: Other1 -1
Slide 13: Sales H1 2026
FINANCIAL REVIEW SALES H1 2026 H1 2026 sales -3.3% yoy in constant currency to € 112.5 million (nominal: -5.1%) € 118.6 million -3.3% at cc € 112.5 YoY million • Strong system sales led by immunoassay, MDx and Immunohematology • Decline in service parts and consumables sales due to temporary logisti
Slide 14: Adjusted EBIT and EBIT Margin H1 2026
FINANCIAL REVIEW ADJUSTED EBIT AND EBIT MARGIN H1 2026 H1 2026 adj. EBIT at € 7.7 million € 8.5 -8.9% Margin with 6.9% almost at the prior year’s level million YoY € 7.7 million • Efficiency measures and structural changes • FX effects -30 bps Margin YoY Margin 7.2% 6.9% • Decreased share of high-ma
Slide 15: Cash Flow and Net Debt H1 2026
FINANCIAL REVIEW CASH FLOW AND NET DEBT H1 2026 € 000s H1 2026 H1 2025 Change Strong cash flow dynamics driven by the reduction in elevated trade receivables following the strong year-end business in 2025 Cash flow – operating activities 29,714 -5,771 n/a Cash flow – investment activities -6,208 -8,
Slide 16: Sales by Operating Divisions H1 2026
FINANCIAL REVIEW SALES BY OPERATING DIVISIONS H1 2026 Sales in € million In % of total sales 60 -14.1% (-11.9% at cc) 100% 50 +13.7% 29.5% 80% 35.3% (+15.4% at cc) 40 -9.0% (-7.8% at cc) 60% 30 53.7 45.3% 46.1 41.0% 20 40% 39.7 34.9 28.8 26.2 -56.2% 10 20% (-56.2% at cc) 24.2% 1.2 0.5 23.2% 0 0% Sys
Slide 17: Financial Guidance for Fiscal Year 2026
OUTLOOK FINANCIAL GUIDANCE FOR FISCAL YEAR 2026 CONSOLIDATED SALES ADJUSTED EBIT MARGIN INVESTMENTS¹ Medium to high ~ 10.0% 6.5 - 8.5% single-digit % growth on a constant-currency approximately the previous year's level (FY of sales for tangible and intangible assets basis 2025: 10.0%) combined (FY
Slide 18: Focus in 2026 and Beyond
OUTLOOK FOCUS IN 2026 AND BEYOND 01 02 03 Maintaining cost discipline New systems into series production Mitigate the dilutive effect throughout the company comprehensive and timely, ensuring foreseen quality of certain parts of the Diatron business on Group and providing the basis for upcoming laun
Slide 19: Targets for Sales and Adjusted EBIT Margin 2028 / 2030
OUTLOOK TARGETS FOR SALES AND ADJUSTED EBIT MARGIN 2028 / 20301,2 SALES TARGETS In million € CAGR 6.0–8.0% 2025 – 2028 CAGR 10% - 12% • Several products in an advanced ramp-up phase set to be main revenue driver 400 CAGR • Slight recovery in MDx system demand post pandemic disruptions 6% - 8% • Init
Slide 20: Launch Pipeline & Market Dynamics
OUTLOOK LAUNCH PIPELINE & MARKET DYNAMICS UPCOMING LAUNCH PIPELINE IVD MARKET TRENDS BY APPLICATION Next-generation immunoassay system Overall IVD market: low to mid single-digit growth rates Fully automated; extends addressable market for customer due to wider throughput range; drop-in replacement
Slide 21: Rebuilding Profitability Through Business Excellence
OUTLOOK REBUILDING PROFITABILITY THROUGH BUSINESS EXCELLENCE +380 bps >15.0% MARGIN TARGETS: +460 Adjusted EBIT margin of at least 13.0% by 2028 bps >13.0% +50 Adjusted EBIT margin of at least 15.0% by 2030 bps Adjusted EBIT margin 10.0% -230 +100 bps • Pricing measures bps -120 • Targeted portfolio
Slide 22: Corporate Social Responsibility
CORPORATE SOCIAL RESPONSIBILITY Ecological Corporate Social responsibility responsibility governance AS A BASIS FOR TRUST AND FOR A BETTER TOMORROW TOWARDS PEOPLE AND SOCIETY TRANSPARENCY • Global Environmental Policy outlines • Strong policies and measures to promote • Compliance management system
Slide 23: Appendix
f stratecee AP PENDIX
Slide 24: Financial Calendar 2026
APPENDIX FINANCIAL CALENDAR 2026 Publication 12 NOV 2026 Quarterly Statement 9M | 2026 November 12, 2026 24
Slide 25: Key Figures at a Glance
APPENDIX KEY FIGURES AT A GLANCE1 IFRS (€ million) 2020 2021 2022 2023 2024 2025 Sales 250.1 287.3 274.6 270.4 257.6 250.9 Adjusted EBIT 41.7 54.3 45.1 30.4 33.5 25.2 Adjusted EBIT margin (%) 16.7 18.9 16.4 11.2 13.0 10.0 Adjusted consolidated net income 35.2 45.1 34.7 19.0 20.5 14.2 Adjusted earnin
Slide 26: Shareholder Structure
APPENDIX SHAREHOLDER STRUCTURE (AS OF MAY 2026) SHARE IPO Aug. 1998 Number of shares 12,157,841 Share price (2026-10-01) € 22.00 Market capitalization € 267 million Institutional investors > 10%¹ Briarwood Capital Partners (Aalap Mahadevia) · Morgan Stanley Institutional investors > 3%¹ Brown Capita
Slide 27: Thank You for Your Attention
CONTACT STRATEC SE THANK YOU Gewerbestr. 37 75217 Birkenfeld FOR YOUR Germany ATTENTION Phone +49 7082 7916-0 Fax +49 7082 7916-999 www.stratec.com CONTACT Jan Keppeler, CFA Head of Investor Relations, Sustainability & Corporate Communications Phone +49 7082 7916-6515 j.keppeler@stratec.com 27